IL315645A - Combination therapies comprising a sos1 inhibitor and an egfr inhibitor - Google Patents

Combination therapies comprising a sos1 inhibitor and an egfr inhibitor

Info

Publication number
IL315645A
IL315645A IL315645A IL31564524A IL315645A IL 315645 A IL315645 A IL 315645A IL 315645 A IL315645 A IL 315645A IL 31564524 A IL31564524 A IL 31564524A IL 315645 A IL315645 A IL 315645A
Authority
IL
Israel
Prior art keywords
combination
inhibitor
use according
egfr inhibitor
sos1
Prior art date
Application number
IL315645A
Other languages
English (en)
Hebrew (he)
Inventor
Jacob Haling
Shilpi Khare
Original Assignee
Mirati Therapeutics Inc
Jacob Haling
Shilpi Khare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc, Jacob Haling, Shilpi Khare filed Critical Mirati Therapeutics Inc
Publication of IL315645A publication Critical patent/IL315645A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL315645A 2022-04-08 2023-03-13 Combination therapies comprising a sos1 inhibitor and an egfr inhibitor IL315645A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263329090P 2022-04-08 2022-04-08
PCT/US2023/015097 WO2023196086A2 (en) 2022-04-08 2023-03-13 Combination therapies comprising a sos1 inhibitor and an egfr inhibitor

Publications (1)

Publication Number Publication Date
IL315645A true IL315645A (en) 2024-11-01

Family

ID=88243368

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315645A IL315645A (en) 2022-04-08 2023-03-13 Combination therapies comprising a sos1 inhibitor and an egfr inhibitor

Country Status (10)

Country Link
US (1) US20250177410A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504171A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025512999A (cg-RX-API-DMAC7.html)
KR (1) KR20240170920A (cg-RX-API-DMAC7.html)
CN (1) CN119031916A (cg-RX-API-DMAC7.html)
AU (1) AU2023250819A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245678A1 (cg-RX-API-DMAC7.html)
IL (1) IL315645A (cg-RX-API-DMAC7.html)
MX (1) MX2024012445A (cg-RX-API-DMAC7.html)
WO (1) WO2023196086A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250059182A1 (en) * 2021-06-21 2025-02-20 Mirati Therapeutics, Inc. Sos1 inhibitors
WO2025090808A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Combinations of sos-1 inhibitors with osimertinib and/or met inhibitors to treat cancer
WO2025090810A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Use of sos1 inhibitors and amivantamab to treat cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2593005A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
EP3558979B1 (en) * 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US20230101312A1 (en) 2020-02-24 2023-03-30 Mirati Therapeutics, Inc. Sos1 inhibitors
EP4188383A4 (en) 2020-07-28 2025-01-08 Mirati Therapeutics, Inc. SOS1 INHIBITORS
CA3196287A1 (en) * 2020-10-20 2022-04-28 Binhua Lv Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof
CA3221608A1 (en) * 2021-06-14 2022-12-22 Kumquat Biosciences Inc. Fused heteroaryl compounds useful as anticancer agents

Also Published As

Publication number Publication date
MX2024012445A (es) 2024-11-08
CA3245678A1 (en) 2023-10-12
EP4504171A4 (en) 2026-03-18
JP2025512999A (ja) 2025-04-22
CN119031916A (zh) 2024-11-26
WO2023196086A3 (en) 2023-12-07
KR20240170920A (ko) 2024-12-05
EP4504171A2 (en) 2025-02-12
WO2023196086A2 (en) 2023-10-12
US20250177410A1 (en) 2025-06-05
AU2023250819A1 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
IL311834A (en) Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods
FI3849537T3 (fi) Yhdistelmäterapioita
IL311863A (en) Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods
JP2025000629A5 (cg-RX-API-DMAC7.html)
IL274601B2 (en) Kras g12c inhibitors
JP2025000632A5 (cg-RX-API-DMAC7.html)
JP2025000630A5 (cg-RX-API-DMAC7.html)
JP2024537140A5 (cg-RX-API-DMAC7.html)
JP2024537136A5 (cg-RX-API-DMAC7.html)
CA2758300C (en) Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
CN103200822B (zh) 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用
IL314486A (en) Quinazoline compounds inhibit PAN-KRAS
JP2023540809A5 (cg-RX-API-DMAC7.html)
JP2024537137A5 (cg-RX-API-DMAC7.html)
JP2023507571A5 (cg-RX-API-DMAC7.html)
US9155726B2 (en) Method of treatment using checkpoint kinase 1 inhibitors
AU2007345952A1 (en) Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates
JP2025512999A5 (cg-RX-API-DMAC7.html)
IL315648A (en) Combination therapy of SOS1 inhibitor and MEK inhibitor
Marco-Contelles et al. Editorial [Hot topic: the medicinal chemistry of hybrid-based drugs targeting multiple sites of action (Guest Editors: Jose Marco-Contelles, & Elena Soriano)]
WO2007123511A2 (en) Dosing regimens for the treatment of cancer
IL319808A (en) Combined treatments
CN120693329A (zh) 2-(4-(4-(氨基甲基)-1-氧代-1,2-二氢酞嗪-6-基)-1-甲基-1h-吡唑-5-基)-4-氯-6-环丙氧基-3-氟苄腈的晶形
KR20030065564A (ko) 벤조일피리다진
EP1357904A2 (de) Verwendung von pyrazolo 4,3-d]pyrimidinen